ZYDUSLIFE:NSE:NSE-Zydus Lifesciences Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 975.8

Change

0.00 (0.00)%

Market Cap

USD 978.76B

Volume

0.85M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-04 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
DIVISLAB:NSE Divi's Laboratories Limited

-156.65 (-2.59%)

USD 1,561.24B
MANKIND:NSE Mankind Pharma Ltd

-53.00 (-1.80%)

USD 1,185.39B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-2.30 (-0.17%)

USD 1,157.53B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

-39.90 (-1.17%)

USD 1,152.44B
LUPIN:NSE Lupin Limited

-8.55 (-0.36%)

USD 1,016.49B
AUROPHARMA:NSE Aurobindo Pharma Limited

-6.65 (-0.50%)

USD 737.59B
ALKEM:NSE Alkem Laboratories Limited

+24.35 (+0.44%)

USD 665.89B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

-12.35 (-0.75%)

USD 447.54B
IPCALAB:NSE IPCA Laboratories Limited

-16.00 (-0.92%)

USD 421.90B
AJANTPHARM:NSE Ajanta Pharma Limited

+73.50 (+2.56%)

USD 380.23B

ETFs Containing ZYDUSLIFE:NSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 0.21% 48% F 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.21% 48% F 42% F
Trailing 12 Months  
Capital Gain 36.62% 53% F 70% C-
Dividend Return 0.42% 48% F 35% F
Total Return 37.04% 54% F 70% C-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 44.02% 71% C- 59% D-
Dividend Return 44.53% 71% C- 58% F
Total Return 0.52% 50% F 43% F
Risk Return Profile  
Volatility (Standard Deviation) 37.68% 71% C- 66% D+
Risk Adjusted Return 118.19% 97% N/A 91% A-
Market Capitalization 978.76B 93% A 95% A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.